{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:03:47Z","timestamp":1777536227840,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key R&D Program of China","award":["2018YFA0902000"],"award-info":[{"award-number":["2018YFA0902000"]}]},{"name":"Key Research and Development Project of Guangdong Province","award":["2022B1111070004"],"award-info":[{"award-number":["2022B1111070004"]}]},{"name":"the Double \u201cFirst-Class\u201d University Project","award":["CPU2022QZ08"],"award-info":[{"award-number":["CPU2022QZ08"]}]},{"name":"the Project Program of the State Key Laboratory of Natural Medicines, China Pharmaceutical University","award":["SKLNMZZ202201"],"award-info":[{"award-number":["SKLNMZZ202201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tyrosine kinase inhibitors have been the standard treatment for patients with Philadelphia chromosome-positive (Ph<jats:sup>+<\/jats:sup>) leukemia. However, a series of issues, including drug resistance, relapse and intolerance, are still an unmet medical need. Here, we report the targeted siRNA-based lipid nanoparticles in Ph<jats:sup>+<\/jats:sup> leukemic cell lines for gene therapy of Ph<jats:sup>+<\/jats:sup> leukemia, which specifically targets a recently identified NEDD8 E3 ligase RAPSYN in Ph<jats:sup>+<\/jats:sup> leukemic cells to disrupt the neddylation of oncogenic BCR-ABL. To achieve the specificity for Ph<jats:sup>+<\/jats:sup> leukemia therapy, a single-chain fragment variable region (scFv) of anti-CD79B monoclonal antibody was covalently conjugated on the surface of OA2-si<jats:italic>RAPSYN<\/jats:italic> lipid nanoparticles to generate the targeted lipid nanoparticles (scFv-OA2-si<jats:italic>RAPSYN<\/jats:italic>). Through effectively silencing <jats:italic>RAPSYN<\/jats:italic> gene in leukemic cell lines by the nanoparticles, BCR-ABL was remarkably degraded accompanied by the inhibition of proliferation and the promotion of apoptosis. The specific targeting, therapeutic effects and systemic safety were further evaluated and demonstrated in cell line-derived mouse models. The present study has not only addressed the clinical need of Ph<jats:sup>+<\/jats:sup> leukemia, but also enabled gene therapy against a less druggable target.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12951-024-02505-5","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:02:02Z","timestamp":1715572922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN"],"prefix":"10.1186","volume":"22","author":[{"given":"Yanzi","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiulin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caoyun","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1200\/JCO.2010.33.9176","volume":"29","author":"H Kantarjian","year":"2011","unstructured":"Kantarjian H, Cortes J. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:1512\u20136.","journal-title":"J Clin Oncol"},{"key":"2505_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/sj.leu.2400974","volume":"12","author":"V Najfeld","year":"1998","unstructured":"Najfeld V, Geller M, Troy K, Scalise A. Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event. Leukemia. 1998;12:517\u20139.","journal-title":"Leukemia"},{"key":"2505_CR3","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619\u201330.","journal-title":"Blood"},{"key":"2505_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer. 2008;8:341\u201350.","journal-title":"Nat Rev Cancer"},{"key":"2505_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-023-00811-z","volume":"13","author":"A Walia","year":"2023","unstructured":"Walia A, Prasad V. Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm. Blood Cancer J. 2023;13:36.","journal-title":"Blood Cancer J"},{"key":"2505_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","volume":"27","author":"ED Pulte","year":"2022","unstructured":"Pulte ED, Chen H, Price LSL, Gudi R, Li H, Okusanya OO, Ma L, Rodriguez L, Vallejo J, Norsworthy KJ, et al. FDA approval summary: Revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial. Oncologist. 2022;27:149\u201357.","journal-title":"Oncologist"},{"key":"2505_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Rev. 2021;49: 100825.","journal-title":"Blood Rev"},{"key":"2505_CR8","doi-asserted-by":"publisher","unstructured":"Zhao M, Li X, Zhang Y, Qiao C, Qin Y, Li Z, Li Q, Wang S, Yang Y, Chen Y. RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia. eLife. 2024. https:\/\/doi.org\/10.7554\/eLife.88375.2.sa2","DOI":"10.7554\/eLife.88375.2.sa2"},{"key":"2505_CR9","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1080\/15384101.2019.1646068","volume":"18","author":"M Bahjat","year":"2019","unstructured":"Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ. The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors. Cell Cycle. 2019;18:2307\u201322.","journal-title":"Cell Cycle"},{"key":"2505_CR10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1158\/0008-5472.CAN-17-1733","volume":"78","author":"C Liu","year":"2018","unstructured":"Liu C, Nie D, Li J, Du X, Lu Y, Li Y, Zhou J, Jin Y, Pan J. Antitumor effects of blocking protein neddylation in T315I-BCR-ABL leukemia cells and leukemia stem cells. Cancer Res. 2018;78:1522\u201336.","journal-title":"Cancer Res"},{"key":"2505_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neuroscience.2009.05.057","volume":"163","author":"Y Lee","year":"2009","unstructured":"Lee Y, Rudell J, Ferns M. Rapsyn interacts with the muscle acetylcholine receptor via alpha-helical domains in the alpha, beta, and epsilon subunit intracellular loops. Neuroscience. 2009;163:222\u201332.","journal-title":"Neuroscience"},{"key":"2505_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.neuron.2016.10.023","volume":"92","author":"L Li","year":"2016","unstructured":"Li L, Cao Y, Wu H, Ye X, Zhu Z, Xing G, Shen C, Barik A, Zhang B, Xie X, et al. Enzymatic activity of the scaffold protein rapsyn for synapse formation. Neuron. 2016;92:1007\u201319.","journal-title":"Neuron"},{"key":"2505_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neuron.2007.06.031","volume":"55","author":"F Chen","year":"2007","unstructured":"Chen F, Qian L, Yang ZH, Huang Y, Ngo ST, Ruan NJ, Wang J, Schneider C, Noakes PG, Ding YQ, et al. Rapsyn interaction with calpain stabilizes AChR clusters at the neuromuscular junction. Neuron. 2007;55:247\u201360.","journal-title":"Neuron"},{"key":"2505_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0896-6273(95)90069-1","volume":"15","author":"ED Apel","year":"1995","unstructured":"Apel ED, Roberds SL, Campbell KP, Merlie JP. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex. Neuron. 1995;15:115\u201326.","journal-title":"Neuron"},{"key":"2505_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bph.13697","volume":"174","author":"FK Fuh","year":"2017","unstructured":"Fuh FK, Looney C, Li D, Poon KA, Dere RC, Danilenko DM, McBride J, Reed C, Chung S, Zheng B, et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br J Pharmacol. 2017;174:628\u201340.","journal-title":"Br J Pharmacol"},{"key":"2505_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","volume":"328","author":"W Chen","year":"2020","unstructured":"Chen W, Yuan Y, Jiang X. Antibody and antibody fragments for cancer immunotherapy. J Control Release. 2020;328:395\u2013406.","journal-title":"J Control Release"},{"key":"2505_CR17","first-page":"769","volume":"10","author":"IA Astsaturov","year":"1996","unstructured":"Astsaturov IA, Matutes E, Morilla R, Seon BK, Mason DY, Farahat N, Catovsky D. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia. Leukemia. 1996;10:769\u201373.","journal-title":"Leukemia"},{"key":"2505_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1080\/10717544.2022.2063454","volume":"29","author":"S He","year":"2022","unstructured":"He S, Zhao C, Tao H, Sheng W, Gao R, Liu X, Zhen Y. A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Drug Deliv. 2022;29:1243\u201356.","journal-title":"Drug Deliv"},{"key":"2505_CR19","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1039\/C9BM00494G","volume":"7","author":"Z Lin","year":"2019","unstructured":"Lin Z, Bao M, Yu Z, Xue L, Ju C, Zhang C. The development of tertiary amine cationic lipids for safe and efficient siRNA delivery. Biomater Sci. 2019;7:2777\u201392.","journal-title":"Biomater Sci"},{"key":"2505_CR20","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3390\/ijms21072298","volume":"21","author":"L Tomasello","year":"2020","unstructured":"Tomasello L, Vezzalini M, Boni C, Bonifacio M, Scaffidi L, Yassin M, Al-Dewik N, Takam Kamga P, Krampera M, Sorio C. Regulative loop between \u03b2-catenin and protein tyrosine receptor type \u03b3 in chronic myeloid leukemia. Int J Mol Sci. 2020;21:2298.","journal-title":"Int J Mol Sci"},{"key":"2505_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9\u201326.","journal-title":"Dev Cell"},{"key":"2505_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19:23\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"2505_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, Hines J, Crews CM. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew Chem Int Ed Engl. 2016;55:807\u201310.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2505_CR24","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","volume":"79","author":"GM Burslem","year":"2019","unstructured":"Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated targeted protein degradation. Cancer Res. 2019;79:4744\u201353.","journal-title":"Cancer Res"},{"key":"2505_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.gt.3302328","volume":"12","author":"M Scherr","year":"2005","unstructured":"Scherr M, Battmer K, Schultheis B, Ganser A, Eder M. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther. 2005;12:12\u201321.","journal-title":"Gene Ther"},{"key":"2505_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/1566523221666210217155233","volume":"21","author":"A Singh","year":"2021","unstructured":"Singh A, Bhatia P. Effective downregulation of BCR-ABL tumorigenicity by RNA targeted CRISPR-Cas13a. Curr Gene Ther. 2021;21:270\u20137.","journal-title":"Curr Gene Ther"},{"key":"2505_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.apsb.2020.11.009","volume":"11","author":"L Jiang","year":"2021","unstructured":"Jiang L, Wang Y, Li Q, Tu Z, Zhu S, Tu S, Zhang Z, Ding K, Lu X. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B. 2021;11:1315\u201328.","journal-title":"Acta Pharm Sin B"},{"key":"2505_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104850","volume":"9","author":"B Ma","year":"2022","unstructured":"Ma B, Feng H, Feng C, Liu Y, Zhang H, Wang J, Wang W, He P, Niu F. Kill two birds with one stone: a multifunctional dual-targeting protein drug to overcome Imatinib resistance in philadelphia chromosome-positive leukemia. Adv Sci (Weinh). 2022;9: e2104850.","journal-title":"Adv Sci (Weinh)"},{"key":"2505_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/377232a0","volume":"377","author":"M Gautam","year":"1995","unstructured":"Gautam M, Noakes PG, Mudd J, Nichol M, Chu GC, Sanes JR, Merlie JP. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature. 1995;377:232\u20136.","journal-title":"Nature"},{"key":"2505_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00491-z","author":"Z Fu","year":"2021","unstructured":"Fu Z, Zhang X, Zhou X, Ur-Rehman U, Yu M, Liang H, Guo H, Guo X, Kong Y, Su Y, et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. Cell Res. 2021. https:\/\/doi.org\/10.1038\/s41422-021-00491-z.","journal-title":"Cell Res"},{"key":"2505_CR31","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1038\/509S52a","volume":"509","author":"L Gravitz","year":"2014","unstructured":"Gravitz L. Therapy: this time it\u2019s personal. Nature. 2014;509:S52-54.","journal-title":"Nature"},{"key":"2505_CR32","doi-asserted-by":"publisher","DOI":"10.1039\/D2BM01549H","author":"Z Yu","year":"2022","unstructured":"Yu Z, Wu M, Huang Y, Wang Y, Chen Y, Long Q, Lin Z, Xue L, Ju C, Zhang C. Single-component lipid nanoparticles for engineering SOCS1 gene-silenced dendritic cells to boost tumor immunotherapy. Biomater Sci. 2022. https:\/\/doi.org\/10.1039\/D2BM01549H.","journal-title":"Biomater Sci"},{"key":"2505_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/724360","volume":"2013","author":"A Hamad","year":"2013","unstructured":"Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int. 2013;2013: 724360.","journal-title":"Stem Cells Int"},{"key":"2505_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41556-020-0507-y","volume":"22","author":"JM Perry","year":"2020","unstructured":"Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, et al. Overcoming Wnt-\u03b2-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020;22:689\u2013700.","journal-title":"Nat Cell Biol"},{"key":"2505_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341\u20136.","journal-title":"Nature"},{"key":"2505_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","volume":"79","author":"W Warda","year":"2019","unstructured":"Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells. Cancer Res. 2019;79:663\u201375.","journal-title":"Cancer Res"},{"key":"2505_CR37","doi-asserted-by":"crossref","unstructured":"Herrera AF, Patel MR, Burke JM, Advani R, Cheson BD, Sharman JP, Penuel E, Polson AG, Liao CD, Li C, et al: Anti-CD79B antibody-drug conjugate DCDS0780A in patients with B-Cell non-Hodgkin lymphoma: phase 1 dose-escalation study. Clin Cancer Res 2022.","DOI":"10.1158\/1078-0432.22486925.v1"},{"key":"2505_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41375-019-0607-5","volume":"34","author":"D Jiang","year":"2020","unstructured":"Jiang D, Tian X, Bian X, Zhu T, Qin H, Zhang R, Xu Y, Pan Z, Huang H, Fu J, et al. T cells redirected against Ig\u03b2 for the immunotherapy of B cell lymphoma. Leukemia. 2020;34:821\u201330.","journal-title":"Leukemia"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02505-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02505-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02505-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:04:41Z","timestamp":1715573081000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02505-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02505-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A Chinese patent application was filed with the number of 202211563690.2. China Pharmaceutical University owns the patent rights, and Y. C., C. Z., Y. S., C. J., Y. H. and C.L. are the inventors of the patent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}